These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12596359)
1. From genomics to cancer vaccines: patient-tailored or universal vaccines? Nadler LM; Schultze JL Curr Opin Mol Ther; 2002 Dec; 4(6):572-6. PubMed ID: 12596359 [TBL] [Abstract][Full Text] [Related]
2. Telomerase as a universal tumor antigen for cancer vaccines. Beatty GL; Vonderheide RH Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939 [TBL] [Abstract][Full Text] [Related]
3. The use of dendritic cells in cancer immunotherapy. Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210 [TBL] [Abstract][Full Text] [Related]
4. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743 [TBL] [Abstract][Full Text] [Related]
5. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266 [TBL] [Abstract][Full Text] [Related]
7. Melanoma cancer vaccines and anti-tumor T cell responses. Vujanovic L; Butterfield LH J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270 [TBL] [Abstract][Full Text] [Related]
8. Cancer vaccines: preclinical studies and novel strategies. Palena C; Abrams SI; Schlom J; Hodge JW Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657 [TBL] [Abstract][Full Text] [Related]
9. Potency assays for therapeutic live whole cell cancer vaccines. Petricciani J; Egan W; Vicari G; Furesz J; Schild G Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459 [TBL] [Abstract][Full Text] [Related]
10. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
11. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic cancer vaccines. Morris LF; Ribas A Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546 [TBL] [Abstract][Full Text] [Related]
15. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Radvanyi L Int Arch Allergy Immunol; 2004 Feb; 133(2):179-97. PubMed ID: 14764946 [TBL] [Abstract][Full Text] [Related]
16. Vaccines to treat cancer--an old approach whose time has arrived. Hellstrom KE; Hellstrom I J Cell Biochem; 2007 Oct; 102(2):291-300. PubMed ID: 17729239 [TBL] [Abstract][Full Text] [Related]
17. Immune responses to human tumors: development of tumor vaccines. Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571 [TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Greiner J; Döhner H; Schmitt M Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602 [TBL] [Abstract][Full Text] [Related]
19. Considerations on clinical use of T cell immunotherapy for cancer. Plautz GE; Cohen PA; Shu S Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434 [TBL] [Abstract][Full Text] [Related]
20. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]